RU93042873A - PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MAGNETICITY OF CELL IN MAMMALS - Google Patents

PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MAGNETICITY OF CELL IN MAMMALS

Info

Publication number
RU93042873A
RU93042873A RU93042873/14A RU93042873A RU93042873A RU 93042873 A RU93042873 A RU 93042873A RU 93042873/14 A RU93042873/14 A RU 93042873/14A RU 93042873 A RU93042873 A RU 93042873A RU 93042873 A RU93042873 A RU 93042873A
Authority
RU
Russia
Prior art keywords
mammals
composition
cell
treatment
pharmaceutical composition
Prior art date
Application number
RU93042873/14A
Other languages
Russian (ru)
Inventor
Башеро Жак
Дэ Франз Тиэри
Original Assignee
Шеринг-Пло
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шеринг-Пло filed Critical Шеринг-Пло
Publication of RU93042873A publication Critical patent/RU93042873A/en

Links

Claims (1)

Предлагаемая фармацевтическая композиция предназначена для лечения злокачественности B-клетки у млекопитающих, причем согласно изобретению композиция содержит в качестве активного компонента эффективное количество интерлейкина-4. Действие композиции может выражаться в угнетении роста злокачественности B-клетки и в торможении разрастания злокачественной B-клетки у млекопитающих. В качестве активного компонента композиция может содержать интерлейкин-4 человека или рекомбинантное E. Coli - производное интерлейкина-4 человека. Композиция может находиться в форме, пригодной для внутривенного, внутрибрюшинного или подкожного применения. Предлагаемый способ лечения злокачественности B-клетки у млекопитающих, пораженных этой злокачественностью, предусматривает применение эффективного количества интерлейкина-4, например интерлейкин-4 человека или рекомбинантное производное E. Coli - интерлейкина-4 человека, а также примненение указанных веществ в качестве активного компонента при приготовлении лекарственного средства для лечения злокачественности B-клетки у млекопитающих.The proposed pharmaceutical composition is intended for the treatment of B-cell malignancy in a mammal, and according to the invention the composition contains as an active component an effective amount of interleukin-4. The effect of the composition can be expressed in inhibiting the growth of B-cell malignancy and in inhibiting the growth of malignant B-cells in mammals. As an active component, the composition may contain human interleukin-4 or recombinant E. Coli, a derivative of human interleukin-4. The composition may be in a form suitable for intravenous, intraperitoneal or subcutaneous administration. The proposed method for treating B-cell malignancy in mammals affected by this malignancy involves the use of an effective amount of interleukin-4, such as human interleukin-4 or a recombinant derivative of E. Coli - human interleukin-4, as well as the use of these substances as an drug for treating B-cell malignancy in mammals.
RU93042873/14A 1990-12-13 1991-12-10 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MAGNETICITY OF CELL IN MAMMALS RU93042873A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR90403585.4 1990-12-13

Publications (1)

Publication Number Publication Date
RU93042873A true RU93042873A (en) 1996-05-20

Family

ID=

Similar Documents

Publication Publication Date Title
EA200000468A1 (en) THERAPEUTIC COMPOSITION FOR THE ADMINISTRATION OF TOLTERODINE WITH CONTROLLED DELIVERY
KR930702022A (en) Treatment or prevention of type 1 diabetes by oral administration of insulin
SG68567A1 (en) Heterocyclic compounds and their preparation and use
DE69230046D1 (en) 2-bromomelatonin for the treatment of sleep disorders
ZA916579B (en) Heterocyclic compounds and their preparation and use
DE69328186D1 (en) COMPOSITION FOR TREATING PARKINSON'S DISEASE
GEP20002297B (en) Alpha-Substituted Pyrimidine-Thioalhyl and Alkyl-Ether Compounds, Method for Treatment of Individual Infected with the Immunodeficiency Virus
DK0544714T3 (en) Heterocyclic compounds and their preparation and use
RU96111026A (en) 7 - ([1A, 5A, 6A] -6-AMINO-3-AZABICYCLO [3.1.0.] HEX-3-IL) -6-fluoro-1- (2,4-difluorophenyl) -1,4-dihydro -4-OXO-1,8- NAPHTHIRIDINE-3-CARBONIC ACID, METHANESULPHIC ACID SALT, METHOD FOR PRODUCING IT, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT
BR9500436A (en) Products use of a g-csf use of a tnf protein ligand process for the treatment and / or prevention of septic shock
EA199800717A1 (en) METHOD FOR THE TREATMENT OF MAMMAL DISEASES AND THE CYVITTERION COMPOSITION
DE69800859D1 (en) Use of moxonidine to treat neuropathic pain
CA2045605A1 (en) Treatment of leukocyte dysfunction with gm-csf
RU93042873A (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MAGNETICITY OF CELL IN MAMMALS
MY104521A (en) Treatment of depression.
RU2003100517A (en) NEW INTERFERON FOR THE TREATMENT OF MULTIPLE SCLEROSIS
JPS5695116A (en) Xanthine oxidase inhibitor and therapeutic treatment thereby
GR3001793T3 (en) Polyprenyl alcohol-containing injections and use thereof
RU95112520A (en) APPLICATION 4'-IODO-4'-DEOXIDOXORUBICINE FOR THE TREATMENT OF AMYLOIDOSIS, METHOD OF TREATMENT OF AMYLOIDOSIS
GB2260702B (en) Improvements relating to the treatment of haemophilia B by subcutaneous injection of factor 1X
ES2084995T3 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MALIGNANT DISEASES OF LYMPHOCYTES B.
ATE280584T1 (en) USE OF BETA INTERFERON TO PRODUCE A MEDICINAL PRODUCT FOR THE TREATMENT OF EWING'S SARCOMA AND EOE
RU96122371A (en) METHOD FOR TREATING ENDOGENOUS AND POSTOPERATIVE ANALYSIS
RU2001114528A (en) A receptor body that specifically binds a TIE-2 ligand, an isolated nucleic acid molecule, a plasmid, a pharmaceutical composition, a method for preventing or attenuating neovascularization in a mammal
RU94002713A (en) Method for treating children possessing elongated qt interval syndrome